Skip to main content

Advertisement

Table 1 Characteristics of the excluded studies

From: Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis

study Reason for exclusion
Block 2005 Patients: HCC vs. Healthy Tests: immunoblot assay for GP73, AFP not measured. Outcomes: no usable data.
Mao 2008 Suspected overlapped study population with Mao 2010
Chen 2011 Suspected overlapped study population with Mao 2010.
Li 2009a Patients: HCC vs. cholangiocellular carcinoma Tests: GP73, AFP and VEGF expression in tumor, tumor-adjacent and normal liver specimens by immunohistochemistry. Outcomes: no usable data.
Riener 2009a Patients: HCC vs. (healthy and viral hepatitis) Tests: methods for GP73and AFP test not cleared reported Outcomes: no usable data.
Riener 2009b Patients: HCC vs. (chronic HCV infection, bile duct carcinoma and healthy) Test: sera GOLPH2 detection using ELISA, AFP not tested. Outcomes: no usable data.
Stenner 2009 Patients: HCC vs. (HCV, bile duct carcinoma and healthy) Tests: sera GOLPH2 levels by ELISA, unclear whether AFP tested or not. Abstract; no clear data reported.
Li 2009b Patients: HCC vs. (cirrhosis and healthy) Tests: methods for serum GOLPH2 and AFP not reported. Letter; no usable data.
Yamamoto 2009 Patients: HCC Tests: serum GP73 autoantigen/autoantibody and AFP measured Abstract, no usable data.
Yamamoto 2010 Patients: HCC Tests: serum GP 73 autoantigen and autoantibody measured by ELISA. Outcomes: sensitivity/specificity at cutoff points was not calculated.
Tan 2009 Patients: HCC vs. (liver disease without HCC and healthy) Tests: serum GOLPH2 levels by ELISA, AFP not measured. Outcomes: sensitivity, specificity and cut off value were available, but AFP levels were not tested.
Gu 2009 Patients: HCC vs. cirrhosis Tests: GP73 by ELISA, AFP not tested. Outcomes: sensitivity, specificity and cut off value were available, but AFP levels were not tested.